SARC031: A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination With the mTOR Inhibitor Sirolimus for Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2019
At a glance
- Drugs Selumetinib (Primary) ; Vistusertib (Primary)
- Indications Nerve sheath neoplasms; Neurofibromatoses
- Focus Therapeutic Use
- 07 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 1 Feb 2019.
- 02 Oct 2018 Planned initiation date changed from 1 Oct 2018 to 1 Dec 2018.
- 23 Jul 2018 Planned initiation date changed from 1 Jul 2018 to 1 Oct 2018.